Warning: The NCBI web site requires JavaScript to function. more...
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.
Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, Dieudé P, Meyer O, Chollet Martin S.
Arthritis Res Ther. 2008;10(6):R142. Epub 2008 Dec 10.
Related citations
Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
J Rheumatol. 2007 Aug;34(8):1658-63. Epub 2007 Jul 1.
Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
Arthritis Rheum. 2008 Jan;58(1):36-45.
The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X, Jia R, Zhao J, Li Z.
J Rheumatol. 2009 Jun;36(6):1136-42. Epub 2009 May 15.
Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, Sengül A.
Protein Pept Lett. 2008;15(3):314-7.
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.
Joint Bone Spine. 2009 May;76(3):248-53. Epub 2009 Feb 8.
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
Arthritis Rheum. 2009 Aug;60(8):2232-41.
Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M.
Arthritis Res Ther. 2006;8(4):R119.
Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis.
Wagner E, Skoumal M, Bayer PM, Klaushofer K.
Rheumatol Int. 2009 Sep;29(11):1315-21. Epub 2009 Jan 28.
Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis.
Tesija-Kuna A, Grazio S, Miler M, Vukasovic I, Peric P, Vrkic N.
Clin Rheumatol. 2010 May;29(5):487-93. Epub 2010 Jan 13.
Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, Lundberg K, Engström A, Venables PJ, Toes RE, Holmdahl R, Klareskog L, Malmström V.
Arthritis Rheum. 2010 Jan;62(1):44-52.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1.
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM.
Rheumatol Int. 2005 Nov;26(1):58-62. Epub 2005 Feb 23.
Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR.
Arthritis Rheum. 2007 Aug;56(8):2503-11.
Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis.
Sghiri R, Bouajina E, Bargaoui D, Harzallah L, Fredj HB, Sammoud S, Ghedira I.
Rheumatol Int. 2008 Nov;29(1):59-62. Epub 2008 May 22.
[Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Us D, Gülmez D, Hasçelik G.
Mikrobiyol Bul. 2003 Apr-Jun;37(2-3):163-70. Turkish.
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
Ann Rheum Dis. 2004 Oct;63(10):1218-21.
Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.
Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N.
Clin Chem Lab Med. 2009;47(12):1525-30.
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, Uhlig T, Gaarder PI, Kvien TK.
Ann Rheum Dis. 2010 Feb;69(2):345-51. Epub 2009 Jul 30.
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.
Inanc N, Dalkilic E, Kamali S, Kasapoglu-Günal E, Elbir Y, Direskeneli H, Inanc M.
Clin Rheumatol. 2007 Jan;26(1):17-23. Epub 2006 Mar 15.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on